title: Impact of prenatal exposure to psychotropic drugs on neonatal outcome in infants of mothers with serious psychiatric illnesses.
abstract: OBJECTIVE
  To assess whether prenatal exposure to 4 major classes of psychotropic drugs compared with no exposure differed with respect to neonatal outcome.
  
  
  METHODS
  We used the database collected from 13 mother-baby units (MBUs) by the French Network of MBUs. The Marcé Clinical Checklist was used to collect data from maternal interview and clinical record with respect to maternal demographic and clinical characteristics, prenatal exposure to psychotropic drugs, and neonatal outcome (birth weight, preterm birth, neonatal hospitalization). Multivariate logistic regression was used to explore the independent impact of each therapeutic class of psychotropic drug (antipsychotics, antidepressants, mood stabilizers, and anxiolytics/hypnotics) on infant outcomes. All the models were adjusted for maternal confounding factors.
  
  
  RESULTS
  The sample included 1,071 women and their infants. Nearly half (40.2%) used at least 1 psychotropic drug during pregnancy. The risk of low birth weight was increased by antenatal exposure to mood stabilizers (adjusted odds ratio [aOR] = 2.04, 95% confidence interval [CI] = 1.03-4.04, P = .04). The risk of neonatal hospitalization was increased by prenatal exposure to antipsychotics (aOR = 1.74, 95% CI = 1.19-2.54, P = .004), antidepressants (aOR = 1.59, 95% CI = 1.05-2.41, P = .03) or anxiolytics/hypnotics (aOR = 1.89, 95% CI = 1.30-2.75, P = .001), independent of birth weight and term delivery status.
  
  
  CONCLUSIONS
  Infants exposed to psychotropic drugs during pregnancy have less optimal neonatal outcome than unexposed infants and should be considered as a high-risk population.
authors.affiliation: Centre Hospitalier Charles Perrens, 121 rue de la Béchade, CS 81285, F-33076 Bordeaux Cedex, France alsutter@ch-perrens.fr.
authors.forename: Anne-Laure
authors.initials: AL
authors.lastname: Sutter-Dallay
authors.forename: Mélanie
authors.initials: M
authors.lastname: Bales
authors.forename: Elodie
authors.initials: E
authors.lastname: Pambrun
authors.forename: Nine M-C
authors.initials: NM
authors.lastname: Glangeaud-Freudenthal
authors.forename: Katherine L
authors.initials: KL
authors.lastname: Wisner
authors.forename: Hélène
authors.initials: H
authors.lastname: Verdoux
mesh_terms: D000328:Adult; D014151:Anti-Anxiety Agents / Q000009:adverse effects*; D000928:Antidepressive Agents / Q000009:adverse effects*; D018692:Antimanic Agents / Q000009:adverse effects*; D014150:Antipsychotic Agents / Q000009:adverse effects*; D001724:Birth Weight / Q000187:drug effects; D005260:Female; D005602:France / Q000453:epidemiology; D006801:Humans; D006993:Hypnotics and Sedatives / Q000009:adverse effects*; D007231:Infant, Newborn; D007232:Infant, Newborn, Diseases / Q000139:chemically induced / Q000453:epidemiology*; D001523:Mental Disorders / Q000188:drug therapy / Q000453:epidemiology*; D009035:Mothers; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy / Q000453:epidemiology*; D047928:Premature Birth / Q000139:chemically induced / Q000453:epidemiology*; D011297:Prenatal Exposure Delayed Effects / Q000453:epidemiology*; D012306:Risk
chemical_list: D014151:Anti-Anxiety Agents; D000928:Antidepressive Agents; D018692:Antimanic Agents; D014150:Antipsychotic Agents; D006993:Hypnotics and Sedatives